Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2010

View Archived Issues

Cequent describes IND-enabling studies of RNAi drug for adenomatous polyposis

Vascular Biogenics (d/b/a VBL Therapeutics) discloses novel antiinflammatory agents

Antihypertensive efficacy of azilsartan medoxomil demonstrated in multiple studies

Argenta Oral Therapeutics claims dual CRTH2/DP receptor ligands

Next-generation sequencing analysis identifies gene mutations affecting response to panitumumab

Sirtuin expression linked to non-small cell lung cancer

Merck & Co. identifies novel histamine H3 receptor ligands

Chinese scientists claim novel anti-HIV akaloids

Palau Pharma presents novel histamine H4 receptor antagonists

Dual PDK1/AKT inhibitor PHT-427 identified through PHuDock platform

Novel LNA-based antisense oligonucleotides show potent antitumor effects in vivo

Intercell acquires monoclonal antibody discovery platform from Cytos

Stemgent and Miltenyi Biotec form strategic stem cell partnership

MediGene reports results from phase II clinical trial of EndoTAG-1 in breast cancer

Eisai to initiate phase III trial of rufinamide in Lennox-Gastaut syndrome in Japan

Dynavax completes first immunizations in phase III study of Heplisav

Polyphor enters into PEMfinder collaboration with Novartis

Long-lasting effects seen with NGX-4010 in postherpetic neuralgia patients

VX-222 development for hepatitis C advances

Bayer Schering Pharma begins phase III regorafenib trial in mCRC

Aeterna Zentaris receives FDA orphan drug status for AEZS-108 in ovarian cancer

Meda acquires exclusive rights to flupirtine for fibromyalgia

Improvements seen with gene therapy in small study in severe retinal dystrophy

Oramed reports results for phase IIb trial of oral insulin in type 2 diabetes

Alzheimer's Drug Discovery Foundation funds chaperone technology

New FDA dosing guidelines for colchicine given with protease inhibitors

ThromboGenics and BioInvent VTE treatment deemed superior to standard treatment

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...